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1. Abstract 
Extensive DNA methylation is observed in gastric cancer with Epstein-Barr virus 
(EBV) infection, and EBV infection is the cause to induce this extensive 
hypermethylation phenotype in gastric epithelial cells. However, some 5 regions of 
genes do not undergo de novo methylation, despite the induction of methylation in 
surrounding regions, suggesting the existence of a resistance factor against DNA 
methylation acquisition. We conducted an RNA-seq analysis of gastric epithelial 
cells with and without EBV infection and found that TET family genes, especially 
TET2, were repressed by EBV infection at both mRNA and protein levels. TET2 was 
found to be downregulated by EBV transcripts, e.g. BARF0 and LMP2A, and also by 
seven human miRNAs targeting TET2, e.g., miR-93 and miR-29a, which were 
upregulated by EBV infection, and transfection of which into gastric cells repressed 
TET2. Hydroxymethylation target genes by TET2 were detected by 
hydroxymethylated DNA immunoprecipitation sequencing (hMeDIP-seq) with and 
without TET2 overexpression, and overlapped significantly with methylation target 
genes in EBV-infected cells. When TET2 was knocked down by shRNA, EBV 
infection induced de novo methylation more severely, including even higher 
methylation in methylation-acquired promoters or de novo methylation acquisition 
in methylation-protected promoters, leading to gene repression. TET2 knockdown 
alone without EBV infection did not induce de novo DNA methylation. These data 
suggested that TET2 functions as a resistance factor against DNA methylation in 
gastric epithelial cells and repression of TET2 contributes to DNA methylation 
acquisition during EBV infection. 
5 
 
2. Abbreviations 
hMeDIP: hydroxymethylated DNA immunoprecipitation 
MeDIP: methylated DNA immunoprecipitation 
DNMT: DNA methyltransferase  
TSS: transcription start sites 
EBV: Epstein-Barr virus 
RT-PCR: reverse transcription polymerase chain reaction 
TET: Ten-eleven-translocation 
FBS: fetal bovine serum 
cDNA: complementary DNA 
CMV: cytomegalovirus 
miRNA: microRNA 
WT: wild type 
OE: overexpression 
IP buffer: immunoprecipitation buffer 
Tris: tris (hydroxymethyl) aminomethane 
EDTA: ethylenediaminetetraacetic acid 
TE: tris-EDTA 
mRNA: messenger RNA 
SDS: sodium dodecyl sulphate 
6 
 
3. Introduction 
3-1. Epigenetics 
     Epigenetics is heritable information during cell division other than DNA 
sequences, including various histone modifications and DNA modifications. 
Epigenetic status regulates gene expressions leading to phenotypic changes [1]. 
3-1-1. Histone modifications 
     A histone is a octamer consisting of 2 molecules of H2A, H2B, H3 and H4 
respectively. 145-147 bp of DNA wraps around histone proteins to form a 
nucleosome core, and the linker histone H1 binds the nucleosome at the entry and 
the exit sites of the DNA [2-10]. The core histones are mainly globular with the 
exception of their N-terminal tails called histone tails [11]. Amino acid residue of 
histone tails acquire various modifications such as lysine methylation, lysine 
acetylation, arginine methylation, serine phosphorylation, threonine 
phosphorylation, lysine ubiquitylation, lysine sumoylation and so on, influencing 
transcription, repair and replications [11]. 
3-1-2. DNA modifications 
     One of the important DNA modifications is methylation of cytosine at CpG 
nucleotide, which is mainly regulated by three DNA methyltransferases, DNMT1, 
DNMT3a and DNMT3b. DNMT3a and DNMT3b work as de novo 
methyltransferases and DNMT1 works as a maintenance methyltransferase during 
mitosis but is also reported to work as a de novo methyltransferase in cancer cells 
[12, 13]. DNA methylation often occurs on CpG sites at CpG islands. CpG island is a 
genomic DNA region often located around the promoter regions, in which the 
frequency of the CG sequence is high compared to other regions [14]. DNA 
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methylation in CpG islands of the gene promoter regions blocks transcription 
factors from binding to DNA, and also gathers proteins which hold 
Methyl-CpG-binding domain, leading to chromatin structure changes and gene 
repressions [15]. 5-methylcytosine (5mC) at methylated CpG dinucleotide can be 
oxidized to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 
5-carboxylcytosine (5caC) by TET family proteins, which are known as 
demethylating enzymes, and 5fC and 5caC are directly turned unmodified cytosine 
through base excision repair by thymine DNA glycosylase (TDG) (Fig. 1) [16-20]. 
TET family proteins consist of TET1, TET2 and TET3, which are reported to require 
α-ketoglutarate and Fe2+ as coenzymes in oxidation process. 
 
3-2. Epigenomic alterations in cancer 
Aberrant DNA methylation is one of the major epigenomic alterations in 
cancer, and DNA hypermethylation of gene promoter regions inactivates tumor 
suppressor genes and strongly affects cancer development [21-25]. Cancer with high 
Fig. 1: 5mC conversion to 5hmC, 5fC and 
5caC by TET proteins. Modified figure 
from reference [19]. 
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methylation level in gene promoter regions, known as CIMP (CpG island 
methylator phenotype), has been found in colorectal cancer [26], gastric cancer [27], 
glioma [28-32], adult T cell leukemia/lymphoma (ATLL) [33], and many other 
cancers [34]. One of TET family genes, TET1, was first found as a fused protein to 
MLL in acute myeloid leukemia [35, 36] and 15% of various myeloid cancer patients 
have TET2 mutations which cause DNA hypermethylation and induce 
leukemogenesis [33, 37-40]. The subgroup of glioma with extensive promoter 
hypermethylation is known as G-CIMP (Glioma CpG island methylator phenotype) 
and more than 70% of lower-grade gliomas (grades II and III) possess mutations of 
IDH1 and IDH2 which produce α-ketoglutarate, a cofactor of TET family (Fig. 2) 
[28-30, 32]. 
 
3-3. DNA methylator epigenotype   
Fig. 2: Correlation between G-CIMP (Glioma CpG island methylator phenotype) and 
IDH1 mutations. Modified figure from [28]. 
Fig. 3: Three major 
epigenotypes of 
colorectal cancer. 
Colorectal cancer 
is classified into 
high-methylation 
epigenotype (HME), 
intermediate-meth
ylation 
epigenotype (IME) 
and 
low-methylation 
epigenotype (LME) 
[41]. 
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Colorectal cancer can be stratified into 3 major subgourps with unique DNA 
methylation epigenotypes: high-methylation epigenotype (HME), 
intermediate-methylation epigenotype (IME) and low-methylation epigenotype 
(LME) [41]. HME correlated strongly with MSI-high and BRAF-mutation(+), 
whereas IME correlated with KRAS-mutation(+) (Fig. 3). 
For gastric cancer, it also has 3 methylation epigenotypes, EBV-/low 
methylation, EBV-/high methylation and EBV+/high methylation subtypes. The 3 
Fig. 4: Three epigenotypes of gastric cancer, EBV-/low, 
EBV-/high and EBV+/high. PRC-target genes in embryonic 
stem cells are significantly enriched in EBV-/high and 
EBV-/low methylated genes, suggesting a different 
methylation mechanism for EBV+ tumors [42]. 
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epigenotypes are characterized by 3 kinds of genes: genes methylated only EBV+ 
tumors, genes methylated EBV+ and EBV-/high tumors and genes methylated all 3 
kinds of tumors [42]. Polycomb repressive complex (PRC) target genes in embryonic 
stem cells are significantly enriched in EBV-/high and EBV-/low methylated genes, 
suggesting different methylation mechanisms for EBV+ tumors (Fig. 4).  
 
3-4. EBV-associated gastric cancer 
One of the most hypermethylated malignancies is EBV-associated gastric 
cancer [42-48]. Among gastric cancer, 7-15% are EBV-associated gastric cancer 
throughout the world without geographical divergence, and EBV is basically found 
in every malignant cell [45]. Clinical features of EBV-associated gastric cancer 
include male predominance, appearance in the upper part of the stomach and 
abundance of inflammatory cell infiltration [49, 50]. Mutation of ARID1A, a 
member of SWI/SNF family of a nucleosome remodeling complex is also reported 
[51], and MLH1 is not methylated in the promoter region so microsatellite 
instability (MSI) is not detected in EBV associated gastric cancer [47, 52]. Host 
miRNA expression is changed by EBV infection. EBV infection downregulates the 
expression of host miR-200 family whose targets are ZEB1 and ZEB2, and the 
upregulation of ZEB1 and ZEB2 causes CDH1 repression [53]. Latent infection of 
EBV upregulates DNMTs of host cells and extensive methylation is observed first in 
the EBV genome and subsequently in host genome [42, 54]. Although it was 
reported that EBV expressing protein LMP2A induces DNMT1 by phosphorylating 
STAT3 [55], molecular mechanisms of methylation induction during EBV infection 
is largely unknown. 
11 
 
3-4-1. Epstein-Barr virus (EBV) 
Epstein-Barr virus (EBV) is a double stranded DNA virus belonging to 
Herpesviridae family and 90% of adult people are latently infected all over the 
world [56]. EBV infection causes infectious mononucleosis in initial infection and is 
also involved in malignant tumors such as Hodgkin's lymphoma, Burkitt lymphoma, 
T-cell and NK-cell lymphomas, opportunistic lymphoma in immunocompromised 
host, nasopharyngeal carcinoma, and Gastric carcinoma [57-61]. When EBV is 
infected to host cells, genome of EBV is hardly integrated into host genome but 
bound to host genome by two dimers of Epstein–Barr nuclear antigen 1 (EBNA1) 
protein forming episome [62, 63]. Although EBV genome encodes approximately 100 
genes, only limited genes are expressed depends on types of latency, from type I to 
type III. The latency types depend on types of host cells and for gastric cancer, EBV 
shows latency type I as with Burkitt lymphoma. Latency type I is the most limited 
expression and only a few genes such as EBNA1 and LMP2A are expressed. Other 
repressed genes are regulated by DNA methylation [64]. 
 
3-5. Technique for DNA methylation analysis 
In this study, we conducted 3 types of DNA methylation analyses, Infinium 
BeadChip array, pyrosequencing and methylated DNA immunoprecipitation 
sequencing (MeDIP-seq). Bisulfite conversion is conducted before Infinium 
BeadChip array and pyrosequencing. 
3-5-1. Bisulfite conversion 
Bisulfite conversion is the most common method for DNA methylation 
analysis. Unmethylated cytosine is sulfonated and sulfonated cytosine is 
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deaminated by hydrolysis, and it turns to sulfonated uracil. After removal of sulfone 
group by alkali treatment, it turns into uracil which is read as thymine by PCR. On 
the other hand, 5mC doesn’t change in response to bisulfite treatment and is read 
as cytosine itself. Difference of thymine and cytosine enables us to distinguish 
methylation patterns [65]. Since neither 5hmC nor 5mC changes in response to 
bisulfite treatment, 5hmC and 5mC cannot be distinguished in a bisulfite-based 
methylation assay [66, 67]. 
3-5-2. Infinium BeadChip array 
The Infinium HumanMethylation450 BeadChip (Illumina, WG-314-1003) 
contains more than 485,000 individual CpG probes covering 99% of RefSeq genes 
with an average of 17 CpG sites per gene. In each CpG site, ratio of fluorescent 
signal called  value was measured by a methylated probe relative to the sum of 
Fig. 5: The principal of Illumina Infinium HumanMethylation450 BeadChip. 
There are two types of assays, Infinium I assay and Infinium II assay [68]. 
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both methylated and unmethylated probes [68]. The  value, ranging from 0.00 to 
1.00, reflects the methylation level of each CpG site from low to high. While 
Infinium 27K uses one type of assay, Infinium 450K combines two kinds of assays, 
Infinium I assay and Infinium II assay (Fig. 5). In Infinium I assay, there are two 
different probes located on two different bead types. One is for methylated strand, 
and the other is for unmethylated strand. For Infinium II assay, there is one type of 
probe which can bind to both methylated and unmethylated DNA. Guanine with 
green signal is incorporated if DNA is methylated, and adenine with red signal is 
incorporated if DNA is unmethylated. In both assays, the percentage of DNA 
methylation is reported as  value.  
3-5-3. Pyrosequencing 
Pyrosequencing enables us to know which nucleotide is incorporated to 
template strand [69]. When one of the nucleotides is incorporated to template 
strand, released pyrophosphate is converted to ATP by ATP sulfurylase. Luciferase 
generates light signals proportional to ATP molecules released. There are 4 assay 
types in Pyrosequencing; Genotyping (SNP), Allele Quantification (AQ), Sequence 
Analysis (SQA) and Methylation Analysis (CpG). In the Methylation Analysis, the 
ratio of methylation level of specific CpG sites in a region is quantitatively detected. 
When analyzing bisulfite-treated DNA, 5mC is detected as cytosine and unmodified 
cytosine is detected as thymine. Methylation levels are detected as (cytosine / 
cytosine + thymine) × 100 (%). 
3-5-4. Methylated DNA immunoprecipitation sequencing (MeDIP-seq) 
In MeDIP-seq, fragmented DNA was immunoprecipitated by anti-5mC 
antibody. The enriched 5mC regions are read by next generation sequencing. This 
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method enables differentiation between 5mC and 5hmC, that bisulfite based 
methods cannot do, by using different antibodies for 5mC and 5hmC. 
 
3-6. Akata system  
Normally the frequency of EBV infection to epithelial cells is very low, Akata 
system, developed by Takada et al., enables to construct EBV infected epithelial 
cells efficiently [70]. B cell lymphoblast cell line, Akata, derived from EBV+ Burkitt 
lymphoma is infected by EBV latently. By stimulating immunoglobulin G, which is 
expressed on the surface of Akata cells, by anti-IgG antibody, latent infection turns 
into lytic infection and Akata cells release an abundance of EBV. By co-culturing 
lytic Akata cells with gastric epithelial cells, EBV infected gastric epithelial cells 
are constructed. One characteristic of Akata cells is that after EBV is dropping out 
by rounds of passages, reinfection can be conducted. Akata cells used in this study 
were reinfected with EBV holding neomycin resistant gene so that the selection of 
EBV infected cells by G418 is possible. By infecting low-methylation gastric cancer 
cells with EBV applying Akata system, previous studies have demonstrated that 
EBV infection itself causes the induction of extensive hypermethylation [42, 70, 71]. 
 
3-7. Purpose of this study 
Normally in cells, induction and resistance factors for DNA methylation might 
work in balance to maintain methylation status, and aberrant DNA methylation 
may occur when the balance is collapsed for example with EBV infection. To 
investigate the molecular mechanisms by which extensive hypermethylation is 
induced in EBV-positive gastric cancer, a transcriptome analysis of epithelial 
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gastric cancer cells with and without EBV infection was conducted, and TET2 was 
found to be one of the downregulated genes by EBV infection. In this study, we 
investigated if TET2 works as a resistance factor against DNA methylation 
acquisition during EBV infection.  
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4. Results 
4-1. Transcriptome analysis  
4-1-1. Transcriptome analysis by RNA-sequencing 
To identify candidate resistance factors for methylation acquisition during 
EBV infection, we performed an RNA-seq analysis using a low-methylation gastric 
cancer cell line, MKN7 (MKN7_WT), and three previously established EBV-infected 
MKN7 clones (MKN7_EB#1, EB#2, and EB#3) [42]. Downregulated genes in 
response to EBV infection included TET1 and TET2, which encode TET family 
demethylation enzymes (Fig. 6). 
4-1-2. Validation by real-time RT-PCR and immunoblotting analyses 
Quantitative RT-PCR to analyze TET family genes was performed using 
MKN7_WT and MKN7_EB#1. TET2 was markedly downregulated after EBV 
Fig. 6: Downregulation of genes in the TET family in EBV-infected cells. 
Genome-wide gene expression levels were analyzed by RNA-seq. The 
diagram indicates the numbers of genes downregulated by <0.9-fold, 
<0.6-fold and <0.4-fold respectively in three EBV-infected clones 
compared with MKN7_WT. For example for <0.60-fold change, TET1 was 
included in the 3,735 genes that were downregulated in all the three 
clones, and TET2 was downregulated in MKN7_EB#1 and EB#3. 
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Fig. 7: Expression of TET family. (A, B) Expression of TET 
family in mRNA level in MKN7 (A) and GES1 cell lines (B). 
(C, D) Protein expression was also downregulated after EBV 
infection in MKN7 (C) and GES1 cell lines (D). 
infection, and TET1 was expressed at low levels in both cells (Fig. 7A). Another 
gastric epithelial cell line, GES1 (GES1_WT), established from normal gastric 
epithelial cells, was also infected with EBV (GES1_EBV). This cell line acquires 
extensive hypermethylation in response to in vitro EBV infection (Matsusaka et al., 
unpublished data). Based on a quantitative RT-PCR analysis, the three TET family 
genes were downregulated in GES1_EBV, especially TET2 (Fig. 7B). 
Immunoblotting analyses also showed that TET2 protein expression was 
significantly repressed by EBV infection in both MKN7 (Fig. 7C) and GES1 cells 
(Fig. 7D). Since TET2 expression was markedly decreased after EBV infection in 
both MKN7 and GES1 cells among the three TET family genes, and TET2 is 
involved in cytosine hydroxymethylation, we hypothesized that TET2 
downregulation contributes to methylation, at least partially.  
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4-2. Downregulation mechanism of TET2 
To investigate the mechanism which downregulates TET2 expression during 
EBV infection, we first examined if EBV encoded transcripts contribute to decrease 
of TET2. It is known that most of EBV genome is dense methylated in latent 
infection in gastric epithelial cells, and the limited number of protein-coding genes, 
LMP2A and EBNA1, and non-coding transcripts, BARF0 and EBER1/2, are allowed 
to express [49, 54]. These are called latent genes, and were overexpressed in MKN7 
cells. It was found that TET2 was downregulated to 0.35-fold by BARF0, and 
0.65-fold by LMP2A (Fig. 8). 
To examine effects of cellular transcripts on TET2 expression, we next 
Fig. 8: Viral 
factors to 
downregulate TET2. 
Expression level of 
TET2 was analyzed 
in MKN7 
overexpressing EBV 
latent genes, 
LMP2A, ENBA1, BARF0 
and EBER1/2, and 
normalized against 
that of GAPDH. 
BARF0 and LMP2A 
significantly 
downregulated 
TET2.  
Fig. 9: MiRNA microarray 
analysis. Expression of 2,549 
human miRNAs in MKN7_WT and 
the three EBV-infected clones 
were analyzed using a 
microarray. Among 87 miRNAs 
that were expected to target 
TET2 based on an in silico 
analysis, 15, 10, and 24 
miRNAs were upregulated 
>1.3-fold in MKN7_EB#1, EB#2, 
and EB#3, respectively, and 7 
miRNAs were upregulated in all 
the three clones. 
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conducted miRNA microarray analysis for human miRNA expression in MKN7_WT 
and three EBV-infected MKN7 clones. Of 83 candidate miRNAs that targeted TET2 
according to in silico data (http://microrna.org/), 7 miRNAs were commonly 
upregulated in the three EBV-infected MKN7 clones compared to MKN7_WT (Fig. 
9). To validate whether these 7 miRNAs decrease TET2 expression, we transfected 
the miRNAs into MKN7 and another cell line GES1 and performed quantitative 
RT-PCR to analyze TET2. All the 7 miRNAs decreased TET2 expression levels to 
50–85% in MKN7 as well as GES1 cells, suggesting that the upregulation of these 7 
miRNAs downregulates TET2, at least partly (Fig. 10). Downregulation of TET2 
protein was also confirmed by immunoblotting analysis (Fig. 10). Transfection of 
miR-29a and miR-93 induced more marked downregulation in protein level than in 
mRNA level, which is consistent with reports explaining that miRNA works for not 
only mRNA cleavage but also translational repression [72]. The predicted regions 
for the 7 miRNAs to bind 3 UTR of TET2 were analyzed using microRNA.org [73] 
Fig. 10: Validation of miRNA microarray. The 7 miRNAs were transfected into 
MKN7 and GES1, and real-time RT-PCR showed that TET2 expression levels 
decreased by 50-85% after 48 h. Immunoblotting analysis was also conducted for 
TET2 and α-Tubulin expression in GES1 transfected with the 7 miRNAs. 
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and shown (Fig. 11). 
We next searched for human genes targeted by viral miRNAs encoded in EBV 
genome, using computational software Vir-Mir database [74, 75]. No EBV miRNA 
was found to target human TET2 (Supplementary Table S1).  
Fig. 11: The predicted target regions of 7 miRNAs targeting TET2. hsa-miR-29a 
has 4 sites and has-miR-371a has 2 sites to bind 3 UTR of TET2. 
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4-3. Hydroxymethylation target genes of TET2 
To identify hydroxymethylation target genes in response to TET2, we 
performed hMeDIP-seq and MeDIPseq analyses using GES1 cells transfected with 
a TET2-overexpression vector (TET2OE) or mock vector (Mock) (Fig. 12). We 
detected 2,619 hydroxymethylation target genes that showed 5hmC peaks in the 
hMeDIP-seq analysis in both Mock and TET2OE cells. Among 2,619 genes, a 
significant number of genes overlapped with the 3,029 methylation target genes in 
EBV-infected cells (527 genes, P<1×10-15, 2 test) (Fig. 13A). These results suggested 
that many genes remain unmethylated owing to hydroxymethylation by TET2 
before EBV infection, leading to methylation via TET2 depression after EBV 
infection. However, other enzymes, in addition to TET2, may produce 5hmC. To 
Fig. 12: TET2 overexpression. (A) A TET2-expressing vector was 
transfected into GES1 and the expression level of TET2 
relative to GAPDH at 30 days after transfection was analyzed 
by real-time RT-PCR. (B) Immunoblotting analysis was 
conducted for TET2 and α-Tubulin expressed in Mock and TET2OE 
cells. (C) Representative results of hMeDIP-seq and MeDIP-seq 
around FRG1B are shown. The hydroxymethylation level of the 
region was increased in cells with TET2 overexpression, 
whereas the methylation level was increased in EBV infection. 
(D) hMeDIP was repeated, and increase of hmC in 5 region of 
FRG1B was validated by hMeDIP-PCR at the region indicated in 
Figure 12C, and normalized against a positive control region 
NEDD9. (E) Increase of mC was validated by quantitative 
pyrosequencing assay at the region indicated in Figure 12C. 
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specifically analyze TET2 target genes, we focused on 1,231 genes that did not 
possess 5hmC peaks in Mock cells, but acquired 5hmC peaks after TET2 
overexpression. Among these 1,231 genes, more significant overlap with 
methylation target genes was found (346 genes, P<1×10-15, 2 test) (Fig. 13B). These 
Fig. 13: Overlap of 
hydroxymethylated genes and 
methylated genes by EBV 
infection. (A) Among 2,619 
hydroxymethylation target 
genes showing 
hydroxymethylation peaks 
within ±1 kb of the TSS in both 
Mock and TET2OE cells, 527 
genes (20.1%) were methylation 
target genes during EBV 
infection (P<1×10-15). (B) 
Among hydroxymethylation 
target genes in TET2OE, 1,231 
genes showing increased 
hydroxymethylation from Mock 
to TET2OE were extracted as 
hydroxymethylation target 
genes by TET2. As many as 346 
genes (28.1%) were methylation 
target genes during EBV 
infection (P<1×10-15). 
Fig. 14: Increased methylation in EBV infected cells and 
decreased methylation in TET2 overexpressing cells. 
Methylation levels of hydroxymethylation target genes by 
TET2 were analyzed by Infinium, and average β values are 
shown. The 346 methylation target genes during EBV 
infection (Group B) showed marked increases of β values 
in GES1_EBV, while the other 885 genes that were not 
extracted as methylation target genes during EBV infection 
(Group A) showed slight, but still significant increases 
of β values in GES1_EBV. Both genes in Group A and Group 
B showed decreases of β values in TET2OE. 
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346 methylation target genes during EBV infection (Group B in Fig. 13B) showed 
significant decreases in  values when TET2 was overexpressed (P<1×10-15), and 
significant increases after EBV infection (P<1×10-15) (Fig. 14). The other 885 genes 
that were not extracted as methylation target genes during EBV infection (Group A 
in Fig. 13B) showed slight, but significant increases in  values in GES1_EBV 
(P<1×10-15) (Fig. 14). These results suggested that hydroxymethylation by TET2 
protects the unmethylated status of genes before EBV infection, and decreased 
TET2 via EBV infection could promote the methylation of these target genes. 
 
4-4. Knockdown of TET2 accelerated de novo methylation during EBV infection 
If TET2 is a resistance factor for methylation acquisition, the knockdown of 
Fig. 15: Knockdown of TET2 by shRNA. (A) TET2 was knocked down in MKN7 
by infection with a shRNA lentivirus targeting TET2 (shTET2). shNON, 
MKN7 cells infected with non-targeting shRNA. Real-time RT-PCR 
analysis of TET2, normalized against PPIA, showed that the expression 
level of TET2 was lower in shTET2 than shNON cells. After EBV infection 
of shNON and shTET2 cells (shNON_EBV and shTET2_EBV, respectively), 
TET2 levels were lower in shNON_EBV than shNON, and decreased further 
in shTET2_EBV compared with shTET2. (B) While 1,008 genes acquired 
promoter methylation by EBV infection in shNON cells, 3,334 genes 
showed de novo methylation by EBV infection in shTET2 cells, and 950 
genes (94.2%) overlapped in the two cell types. “De novo 
methylation” was defined as >2 probes with β <0.2 that increased 
to β >0.4 within ±1 kb of TSS after EBV infection.  
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TET2 might accelerate methylation acquisition during EBV infection. We therefore 
knocked down TET2 in MKN7 cells by shRNA (shTET2) and infected shTET2 cells 
with EBV (shTET2_EBV) (Fig. 15A). Non-targeting shRNA lentivirus was also 
transfected to obtain control cells (shNON). Seventy two days after EBV infection, 
DNA methylation levels were quantitatively investigated using the Infinium 450k 
BeadChip array. When shNON cells were infected with EBV (shNON_EBV), 1,008 
genes acquired de novo promoter methylation, whereas 3,334 genes acquired de 
novo promoter methylation when shTET2 cells were infected with EBV 
(shTET2_EBV), including as many as 950 of the 1,008 genes in shNON-EBV. While 
most (94%) of the methylation target genes in shNON cells were also methylated in 
shTET2 cells, 2,384 genes were newly methylated in TET2-depleted cells (Fig. 15B).  
Next, among 10,829 genes that were defined as unmethylated in shNON_EBV  
cells, 1,419 genes acquired de novo methylation in shTET2_EBV cells. In contrast, 
among 7,953 genes defined as unmethylated in shTET2_EBV cells, only 28 showed 
de novo methylation in shNON_EBV (P<1×10-15) (Fig. 16). There are 2 kinds of de 
Fig. 16: Increase in methylation target genes by EBV infection in 
TET2-depleted cells. Among 10,829 genes defined as unmethylated in 
shNON_EBV cells, 1,419 genes acquired methylation in shTET2_EBV. In 
contrast, only 28 genes showed differential methylation in shNON_EBV 
among 7,953 genes that were unmethylated in shTET2_EBV (P<1×10-15).  
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novo methylation induced by EBV infection. One is methylation-sensitive which 
acquire complete methylation in their promoter regions, and the other is 
methylation-resistance which underwent de novo methylation in the region 
surrounding the TSS, but maintained an unmethylated status in narrow regions 
around the TSS (Funata et al., unpublished data) (Fig. 17). Among the 1,419 genes 
that showed de novo methylation in shTET2_EBV cells, 498 were 
methylation-sensitive genes (Fig. 18A), and 550 were methylation-resistant genes 
(Fig. 18B). The 498 methylation-sensitive genes, e.g., EGFR, showed decreased 
expression in shTET2_EBV cells, but the 550 methylation-resistant genes, e.g., 
C1orf109, did not show decreased expression in shTET2_EBV cells (Fig. 18). 
Fig. 17: Representation 
of an unmethylated gene 
(HIAT1), a 
methylation-sensitive 
gene (CNKSR1), a 
methylation-resistant 
gene (CCDC24), and an 
originally methylated 
gene (PRKCZ) during EBV 
infection. When de novo 
methylation is induced 
by EBV infection, there 
are two types of 
methylation acquisition 
around promoter regions. 
Methylation-sensitive 
genes undergo complete 
methylation around the 
promoter regions; 
methylation-resistant 
genes undergo 
methylation in regions 
surrounding their 
promoters, but maintain 
an unmethylated status 
in narrow regions around 
the TSS (Funata et al., 
unpublished data). 
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When methylation-sensitive genes (i.e., genes that were completely 
methylated in their promoter regions) in shNON_EBV and shTET2_EBV cells were 
compared, 298 overlapped (Fig. 19A and B) and 1,210 were methylated only in 
shTET2_EBV. The 1,210 genes that acquired complete methylation in shTET2_EBV 
cells only (Group C in Fig. 19A), exhibited significantly higher methylation levels 
(P<1×10-15, Wilcoxon signed-rank test) and lower expression levels (P=2×10-12, 
Wilcoxon signed-rank test) in shTET2_EBV cells than shNON_EBV cells (Fig. 20). 
Interestingly, the 298 genes that acquired complete methylation in both 
shNON_EBV and shTET2_EBV cells (Group D in Fig. 19) also showed significantly 
higher methylation levels (P<1×10-15, Wilcoxon signed-rank test) and lower 
Fig. 18: Increase in methylation levels by EBV infection in 
TET2-depleted cells. (A) Among the 1,419 genes showing 
differential methylation in shTET2_EBV (Fig.16), 498 genes 
became methylation-sensitive genes, acquiring complete 
methylation in the promoter regions. Representative 
methylation levels in the EGFR promoter region are shown. (B) 
Among the 1,419 genes showing differential methylation in 
shTET2_EBV (Fig.16), 550 were methylation-resistant genes, 
acquiring methylation in the regions surrounding promoters, 
but maintaining an unmethylated status in narrow regions 
around the TSS. The methylation levels of the C1orf109 promoter 
region are representatively shown. 
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expression levels (P=7×10-5, Wilcoxon signed-rank test) in shTET2_EBV cells than 
shNON_EBV cells (Fig. 20).
Fig. 20: Increase in methylation levels and decrease in 
expression levels, even in methylation-sensitive genes, by TET2 
knockdown. The 1,210 methylation-sensitive genes in shTET2_EBV 
only (Group C in Fig. 19A) showed significant increases in 
methylation levels (P<1×10-15) and significant decreases in 
expression levels (P=2×10-12) in comparison with the levels 
observed in shNON_EBV. The 298 methylation-sensitive genes in 
both shNON_EBV and shTET2_EBV (Group D in Fig. 19A) also showed 
significant increases in methylation levels (P<1×10-15) and 
significant decreases in expression levels (P=7×10-5) in 
comparison with the levels observed in shNON_EBV. 
Fig. 19: Increase in methylation levels, even in methylation-sensitive genes, 
by TET2 knockdown. (A) The number of methylation-sensitive genes was 339 in 
shNON_EBV, and this increased to 1,508 in shTET2_EBV, with 298 overlapping genes 
(87.9%). (B) SLC45A3 was one of the 298 genes showing complete promoter 
methylation in both shNON_EBV and shTET2_EBV. The methylation level was even 
higher and the expression level was even lower in shTET2_EBV compared with 
shNON_EBV. 
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     Among the 314 methylation-resistant genes in shNON_EBV cells that 
underwent de novo methylation in the region surrounding promoters, but 
maintained an unmethylated status in narrow regions around the TSS, 63 acquired 
complete methylation in the promoter regions (i.e., were classified as 
methylation-sensitive genes) in shTET2_EBV (Group E in Fig. 21). These genes did 
not show decreased expression in shNON_EBV cells, presumably because their TSS 
was protected from methylation, but they were significantly downregulated in 
shTET2_EBV cells, presumably because their TSS acquired complete methylation 
(P=0.006) (Fig. 22A). Complete acquisition of methylation in HTRA1 and its 
repression in shTET2_EBV cells were representatively shown (Fig. 22B), and the 
methylation changes were validated by pyrosequencing (Fig. 22C). Among 949 
Fig. 21: Methylation acquisition in methylation-resistant genes 
in shNON_EBV. Among 314 methylation-resistant genes in shNON_EBV, 
which showed protection of the unmethylated status around the TSS 
in shNON_EBV, 63 genes acquired complete promoter methylation in 
shTET2_EBV, i.e., they became methylation-sensitive by TET2 
depletion (left). Among 949 methylation-resistant genes in 
shTET2_EBV, in contrast, only 1 gene was methylation-sensitive in 
shNON_EBV (middle). Among 339 methylation-sensitive genes in 
shNON_EBV, only 1 gene became methylation-resistant in shTET2_EBV 
(right). 
29 
 
methylation-resistant genes in shTET2_EBV cells, only 1 gene acquired complete 
methylation in the promoter region in shNON_EBV cells (P<1×10-15, 2 test) (Fig. 
21). Additionally, only 1 gene became methylation-resistant in shTET2_EBV cells 
among 339 methylation-sensitive genes in shNON_EBV cells (P<1×10-15, 2 test) 
(Fig. 21). 
 
4-5. No methylation was induced by TET2 knockdown alone 
To analyze the effect of TET2 knockdown, shTET2 and shNON cells were 
cultured without EBV infection, and methylation alterations were analyzed using 
the Infinium BeadChip array (Fig. 23). Knockdown of TET2 expression was 
confirmed in mRNA and protein levels (Fig. 23A). Of 13,150 genes that were defined 
Fig. 22: Expression and a representative gene of methylation acquired 
gene. (A) The 63 genes that became methylation-sensitive in shTET2_EBV 
(Group E in Fig. 21) showed significant decreases in expression by EBV 
infection, only when transfected into TET2-depleted cells (P=0.006). (B) 
Representative methylation status of HTRA1 is shown. HTRA1 promoter 
remained unmethylated in shNON_EBV, but acquired complete promoter 
methylation in shTET2_EBV. Expression was retained in shNON_EBV, but 
silenced in shTET2_EBV cells. (C) Quantitative pyrosequencing assay was 
conducted to validate unmethylated status in shNON_EBV and acquisition of 
promoter methylation in shTET2_EBV at the 5 region of HTRA1 indicated in 
Figure 22B. 
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as unmethylated in shNON cells, none acquired de novo methylation in shTET2 
cells (Fig. 23B). No induction of methylation was detected in unmethylated genes, 
methylation-sensitive genes, or methylation-resistant genes (Fig. 24). These results 
suggested that TET2 depletion is not sufficient to induce de novo methylation, and 
that EBV infection might also trigger other mechanisms in addition to repression of 
a resistant factor.   
Fig. 24: Three representative genes showing no methylation alterations in response 
to the knockdown of TET2. 
Fig. 23: No methylation induction by TET2 knockdown itself, 
without EBV infection. (A) Real-time RT-PCR showed a decrease 
in TET2 expression in shTET2 compared with shNON cells. 
Immunoblotting analysis was conducted for TET2 and -Tubulin 
expression in shNON and shTET2 cells. (B) Among 13,150 genes 
that were unmethylated in shNON, none showed methylation in 
shTET2, i.e., de novo methylation did not occur by TET2 
knockdown alone. 
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5. Discussion 
The previous study showed that EBV infection causes extensive DNA 
methylation in gastric epithelial cells [42, 54]. In this study, we performed a 
transcriptome analysis to identify candidate critical factor(s) that contribute to the 
epigenetic alterations and found that TET2 was downregulated during EBV 
infection. 
 
5-1. Downregulation mechanism of TET2  
For myeloid cancer patients, 15% have TET2 mutation and it leads to DNA 
hypermethylation [33, 37-40]. For EBV infected gastric cancer cells in this study, 
there are 2 kinds of possible mechanisms to downregulate TET2 expression; EBV 
derivative factors such as EBV encoded transcripts and miRNA, and human 
derivative factors such as human miRNA, histone modification changes and DNA 
methylation changes. Firstly for EBV encoded transcripts, protein-coding genes, 
LMP2A and EBNA1, and non-coding transcripts, BARF0 and EBER1/2, are allowed 
to overexpress in MKN7 cell line, and it was found that TET2 was downregulated 
by BARF0 and LMP2A (Fig. 8). Secondly for EBV encoded miRNA, none was found 
to target human TET2 in this study (Supplementary Table S1). Thirdly for human 
encoded miRNA, 7 miRNAs were upregulated by EBV infection in all 3 clones 
investigated, and all the 7 miRNAs decreased TET2 expression in MKN7 as well as 
GES1 cells, suggesting that the upregulation of these 7 miRNAs downregulates 
TET2, at least partly (Fig. 10). Transfection of miR-29a and miR-93 induced more 
marked downregulation in protein level than in mRNA level, which is consistent 
with reports explaining that miRNA works for not only mRNA cleavage but also 
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translational repression [72]. Fourthly for histone changes, active marks H3K4me3 
and H3K27ac decreased after EBV infection in the promoter region of TET2, and it 
may contribute to TET2 downregulation (Funata et al., unpublished data). Lastly 
for DNA methylation changes, methylation level was slightly increased in TET2 
promoter region (unpublished data). It is required to infect EBV to TET2 
overexpressing cells. If DNA methylation doesn’t increase after EBV infection in 
TET2 overexpressing cells, downregulation of TET2 may contribute to TET2 
promoter methylation itself.  
 
5-2. TET2 overexpression analysis  
Since a ChIP-seq-grade anti-TET2 antibody is not available, the detection of 
TET2 binding regions by ChIP-seq was not possible; accordingly, 
hydroxymethylated DNA regions by TET2 overexpression were detected by 
hMeDIP-seq. We performed a hMeDIP-seq analysis using Mock and TETOE cells, 
and identified hydroxymethylated promoter regions that showed 5hmC peaks in 
both cells. These hydroxymethylated genes overlapped significantly with 
methylation target genes in EBV-infected cells. However, hydroxymethylation of 
these genes is not necessarily caused by TET2, but might be related to other TET 
family proteins [16, 17, 20]. To detect hydroxymethylated genes converted by TET2, 
we focused on genes that showed no 5hmC peaks in Mock cells, but were 
hydroxymethylated in TET2OE cells. These hydroxymethylation target genes by 
TET2 showed markedly significant overlap with methylation target genes in 
EBV-infected cells. These results suggested that hydroxymethylation by TET2 is 
involved in protecting DNA from methylation, and that the repression of this 
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resistance factor against DNA methylation may contribute to de novo methylation 
acquisition during EBV infection. 
 
5-3. Analysis of TET2 knockdown and EBV infection 
When TET2 was knocked down, more genes acquired de novo methylation by 
EBV infection, including genes that were resistant to de novo methylation around 
TSS in shNON_EBV cells (Fig. 15-22). This also indicated that TET2 functions as a 
resistance factor against DNA methylation during EBV infection, and TET2 
depletion leads to a loss of protective mechanisms and the acquisition of de novo 
methylation. But these genes were not necessarily hydroxymethylation target genes 
in shNON_EBV cells (data not shown). It is possible that these regions could be 
further oxidized to 5fC and 5caC, which would be excised by thymine DNA 
glycosylase to be converted to unmodified cytosine [16-18, 20]. Furthermore, TET1, 
TET2, and TET3 reportedly bind to DNA without the appearance of 5mC or 5hmC, 
indicating that they may protect DNA from methylation by physically binding to 
DNA, regardless of their catalytic activity [76, 77]. Further investigations are 
necessary to clarify how TET2 works as a resistant factor against methylation 
acquisition. 
 
5-4. TET2 knockdown itself 
Interestingly, TET2 knockdown itself did not induce methylation. It has been 
suggested that additional factor(s) are required to induce de novo methylation 
owing, for example, to the increase in methylation pressure via upregulated DNMTs 
[42], and that TET2 might function in resistance against those factors. EBV 
34 
 
infection might also trigger this pressure, and methylation might not be induced 
without EBV infection, even if the resistant factor is depleted. In transcriptome 
analysis, histone deacetylase HDAC8 was downregulated in EBV-infected clones, 
and genes encoding Polycomb group proteins such as SUZ12 and BMI1 were 
upregulated in EBV-infected clones. Expression changes of these epigenetic factors 
might also be important for epigenomic alteration after EBV infection. To fully 
clarify the molecular mechanism underlying the unique epigenomic phenotype with 
extensive hypermethylation in EBV-positive gastric cancer, further investigations 
are necessary to identify factors that induce methylation pressure and to determine 
how the factors are activated and recruited to methylation target genes. 
 
5-5. DNA methylation in other malignancies 
Other than EBV infected gastric cancer, Helicobacter pylori (H. pylori) is also 
associated with gastric carcinogenesis [78, 79] and its infection induces abberant 
hypermethylation in promoter regions of tumor-suppressor genes such as p16, LOX 
and CDH1 [80]. A specific single nucleotide polymorphism of IL-1β increases gastric 
cancer risk and higher incidence of CDH1 promoter methylation [81, 82]. TET2 is a 
member of TET family proteins converting DNA 5mC to 5hmC, 5fC, and 5caC 
[16-18]. TET2 mutations in various myeloid cancer [37, 38], or mutations of IDH1 
and IDH2 which can inhibit DNA hydroxymethylation by TET enzymes [28-32], in 
low-grade gliomas, have been reported and cause DNA hypermethylation phenotype. 
Here, we showed that TET2 could be downregulated by EBV infection in gastric 
epithelial cells via EBV transcripts and upregulation of human miRNAs targeting 
TET2. Other TET family genes are also of great interest since several 
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comprehensive genomic analyses in gastric cancer revealed mutation of TET1 in 
microsatellite-stable gastric cancers [47], and TET1 was also downregulated by 
EBV infection (Fig. 7).  
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6. Conclusions 
In summary, we found that TET2 is downregulated during EBV infection 
via expression of EBV transcripts and upregulation of human miRNAs 
targeting TET2, and that TET2 may function as a resistance factor against 
DNA methylation in gastric epithelial cells. While TET2 depletion itself does 
not increase the methylation level, the downregulation of TET2 contributes to 
methylation induction by EBV infection.  
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7. Materials and methods 
7-1. Cell culture and treatment 
The gastric cancer cell line MKN7 was obtained from Riken BioResource 
Center Cell Bank and was authenticated by the cell bank using short tandem repeat 
PCR. The normal fetal gastric mucosal cell line GES1, which was immortalized by 
SV40, was obtained from the Beijing Institute for Cancer Research [83]. These cells 
were cultured in RPMI 1640 (Wako, Tokyo, Japan). with 10% fetal bovine serum 
(HyClone SH30910.03; GE Healthcare, Chicago, IL, USA) and 
penicillinstreptomycin (Sigma-Aldrich, St. Louis, MO, USA) at 37 °C in a 5% CO2 
incubator. For in vitro EBV infection of MKN7 and GES1 cells, the Akata system 
was used as previously reported [70]. DNA was extracted using the QIAamp DNA 
Mini Kit (Qiagen, Hilden, Germany). RNA was extracted using the RNeasy Mini Kit 
(Qiagen) following the manufacturer’s protocol, and treated with DNaseI (Qiagen). 
 
7-2. Plasmid construction 
cDNA of TET2 transcript variant 1 was inserted into the EcoRV site of the 
pcDNA5/TO vector. The CMV promoter region of pcDNA5/TO was changed to a 
CAG promoter and hygromycin resistance gene was changed to puromycin 
resistance gene. Beginning at 16 h before transfection, cells were cultured in RPMI 
1640 medium with 10% fetal bovine serum without penicillin-streptomycin in 6-well 
dishes, and 2 μg of the TET2-expressing vector or mock vector was transfected 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The transfectants were 
selected using 2 μg/mL puromycin (Sigma-Aldrich). 
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7-3. Knockdown by shRNA 
To knock down TET2, double-stranded oligonucleotide DNA encoding small 
hairpin RNA (shRNA) against TET2 was cloned into the pLKO.1 vector between 
EcoRI and AgeI sites. Oligonucleotide sequences for shRNA against TET2 (shTET2) 
and control non-target shRNA (shNON) are listed in Table 1. Viral packaging for 
shRNA retrovirus vectors was performed using 293T cells and FuGENE 6 (Promega, 
Madison, WI, USA), and medium containing the virus was collected 48 h after 
transfection. 
 
Table 1: shRNA target sequences in lentivirus 
target 
gene 
strand sequence         
  
TET2 
top CCGGCAGATGCACAGGCCAATTAAGCTCGAGCTTAATTGGCCTGTGCATCTGTTTTTG 
bottom AATTCAAAAACAGATGCACAGGCCAATTAAGCTCGAGCTTAATTGGCCTGTGCATCTG 
  
no 
target 
top CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTTG 
bottom AATTCAAAAACAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTG 
  
Oligonucleotide sequences of shRNA against TET2 (shTET2) and control non-target shRNA 
(shNON), inserted into pLKO.1 vector between EcoRI and AgeI sites, are shown, and 21-mer 
target sequences are underlined. 
 
7-4. Real-time RT-PCR 
cDNA was prepared from 1 μg of total RNA using SuperScript III Reverse 
Transcriptase (ThermoFisher, Waltham, MA, USA). Real-time RT-PCR was 
performed using SYBR Green and CFX96 Touch Real-Time PCR (Bio-Rad 
Laboratories, Hercules, CA, USA). The quantity of mRNA for each gene in a sample 
was estimated by comparisons with standard samples that contained 101 to 106 
gene copies. These levels were normalized to those of GAPDH and PPIA, as 
previously described [84]. The PCR primers and conditions are presented in Table 2. 
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Table 2: Primer sequences for real-time RT-PCR  
  
Gene Primer types Primer Sequence 
Anneal 
(°C) 
Product 
(bp) 
TET1 
Forward CTTACAGAGTTTGGCTACACGAT 
60 93 
Reverse CGGGCAACATTTTCATATTCCAC 
TET2 
Forward ATTGAAACAAGACCAAAAGGCTA 
60 109 
Reverse CTTATCACTCAAATCGGAGACA 
TET3 
Forward CCACGGCTTCCAGACAGACCAC 
60 91 
Reverse CAGGGGCAGCTTTCTCCGTTCCCA 
GAPDH 
Forward CCAGGTGGTCTCCTCTGACTTC 
60 108 
Reverse TCATACCAGGAAATGAGCTTGACA 
PPIA 
Forward ACAGTGCTTGCTGGCAGTTAGA 
60 130 
Reverse CAAATCCGCCACCTCTAGGATAG 
 
7-5. Hydroxymethylated and methylated DNA immunoprecipitation sequencing 
(hMeDIP-seq / MeDIP-seq) 
DNA regions with 5hmC and 5mC were analyzed by hMeDIP and MeDIP, 
respectively. Fragmentation of genomic DNA was performed using a Picoruptor 
(Diagenode, Seraing, Belgium) for 10 sets of 30 s on and 30 s off; 20 μg were 
prepared for hMeDIP and 4 μg were prepared for MeDIP. Fragmented DNA was 
separated into two tubes, and the tubes were incubated at 95 °C for 10 min followed 
by 10 min on ice. Immunoprecipitation (IP) Buffer was added to reach 500 μL; 
subsequently, 2 μL of anti-5hmC antibody (#39769; Active Motif, Carlsbad, CA, 
USA) was added for hMeDIP or 4 μL of anti-5mC antibody (#33D3; Diagenode) was 
added for MeDIP. The components of the buffer are described in Table 3. The tubes 
were rotated at 4 °C overnight. Either 50 μL of 50% Protein A or G Sepharose (GE 
Healthcare) was added to each tube, followed by rotation at 4 °C for 2 h. The 
DNA-bead mixture was moved to columns (Corning, New York, NY, USA) and  
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Table 3: Buffers for DIP experiment 
IP buffer 20 mM tris-HCl pH8.0   
  2 mM EDTA 
  150 mM NaCl 
  1.0% Triton-X100 
Wash buffer 20 mM Tris-HCl pH8.0 
  2 mM EDTA 
  300 mM NaCl 
  0.1% SDS 
  1.0% Triton-X100 
Elution buffer 25 mM Tris-HCl pH8.0 
  10 mM EDTA 
  0.5% SDS 
  100 mM NaCL 
 
centrifuged at 1,000 × g for 1 min at 4 °C. After the flow-through was discarded, the 
beads were subjected to washing steps using 500 μL of IP Buffer twice, 500 μL of 
Wash Buffer 5 times, and 500 μL of TE Buffer twice. Beads were transferred to 
tubes with 400 μL of Elution Buffer and treated with 5 μL of Proteinase K (New 
England Biolabs, Ipswich, MA, USA) at 55 °C for 1 h. After phenol and chloroform 
DNA purification, DNA was eluted with 20 μL of distilled water. Enrichment of 
genomic regions in samples after hMeDIP and MeDIP was validated by real-time 
PCR using primers listed in Table 4. The hMeDIP and MeDIP DNA was used to 
prepare library samples using the NEBNext ChIP-Seq Library Preparation Set for 
Illumina (New England Biolabs) following the manufacturer’s protocol. Deep 
sequencing was performed on the Illumina HiSeq 1500 or NextSeq 500 system 
using the TruSeq Rapid SBS Kit (Illumina, San Diego, CA, USA) in 50-base 
single-end mode according to the manufacturer’s protocol. The FASTQ reads were 
mapped to the hg19 reference sequence (UCSC) using BWA with default settings. 
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The numbers of uniquely mapped reads for hMeDIP samples were 18,046,940 
(Mock) and 16,171,239 (TET2 overexpression). For MeDIP samples, there were 
16,322,113 (WT) and 17,482,843 (EBV) uniquely mapped reads. These hMeDIP-seq 
and MeDIP-seq data were submitted to the NCBI BioSample database (http://www. 
ncbi.nlm.nih.gov/biosample), and the accession numbers are GSM2253669 - 
GSM2253672. To count the number of reads that were mapped to within ±1 kb of 
transcription start sites (TSS), Count Reads version 0.2 was used with a window 
size of 300 bp, and the read count for each window was divided by the total read 
count and expressed as reads per million mapped sequence reads (RPM), as 
previously described [85]. Only high-CpG promoter genes (CpG score ≥0.48) [86] 
were analyzed. 
 
Table 4: Primers for DIP-PCR  
Gene 
Primer 
types 
Primer Sequence 
Anneal 
(°C) 
Product 
(bp) 
hMe/Me 
Positive control regions       
NEDD9 
Forward GCTTCATGCCTGCTACATATACTCC 
60 106 hMe, Me 
Reverse TGTGGTCTGTTTGTGTGTAAGAGG 
HMGA2 
Forward CATGCAGAGCAGCGATTTAAA 
60 99 hMe 
Reverse GCCTTTCTTCTTGCTTTAGGACAA 
ACTB 
Forward GAGGGAAATGAGGGCAGGACTT 
60 127 hMe 
Reverse GCTGCCCTGAGGCACTCTTC 
AJAP1 
Forward CGAGCCAGGTCTGAGGC 
60 77 Me 
Reverse GGTCGCTCACCTGAGTCCTA 
Negative control region 
   
HBB 
Forward GGGCTGAGGGTTTGAAGTCC 
60 89 hMe, Me 
Reverse CCACAGGGTGAGGTCTAAGTG 
Validation region 
   
FRG1B 
Forward CTTCCTCCATCTCTATCGGGCAA 
60 73 hMe 
Reverse CTAATCCTGGAGGCGGCATCTGA 
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7-6. RNA-sequencing (RNA-seq) analysis 
Libraries for RNA-seq were prepared using the TruSeq Stranded mRNA 
Sample Prep Kit (Illumina), following the manufacturer’s protocol. Deep sequencing 
was performed on the Illumina HiSeq 1500 or NextSeq 500 platform using the 
TruSeq Rapid SBS Kit (Illumina) in 50-base single-end mode according to the 
manufacturer’s protocol. The RNA-seq data were submitted to the NCBI BioSample 
database (http://www.ncbi.nlm.nih.gov/ biosample), and the accession numbers are 
GSM2253673 - GSM2253676. TopHat was used to map FASTQ reads and Cufflinks 
was used for transcript assembly. Gene expression levels were expressed as 
fragments per kilobase of exon per million mapped sequence reads (FPKM). When 
expression alterations were analyzed, expression levels are presented as log2 FPKM 
values, excluding genes with log2 FPKM ≤0. 
 
7-7. Infinium assays 
Bisulfite conversion was performed using the Zymo EZ DNA Methylation Kit 
(Zymo Research, Irvine, CA, USA) with 500 ng of genomic DNA for each sample. 
Whole genome amplification, labeling, hybridization, and scanning were performed 
according to the manufacturer’s protocols. Genes were classified into the following 
four types based on methylation alterations within ±1 kb of a TSS. (i) 
“Unmethylated genes” contained >2 probes with  <0.2 in wild-type cells and no 
probes with  >0.4 after EBV infection. (ii) “Methylated genes” contained >2 probes 
with  <0.2 in wild-type cells and >2 probes with  from <0.2 to >0.4 after EBV 
infection. Among “Methylated genes,” (iii) “Methylation-sensitive genes” were those 
in which all probes showed  >0.2 after EBV infection, and (iv) 
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“Methylation-resistant genes” were those in which >2 probes in a row showed  <0.2 
even after EBV infection (Fig. 17). 
In a bisulfite-based methylation assay, 5hmC and 5mC cannot be 
distinguished [66, 67]. Unmethylated cytosine changes to uracil, which is read as 
thymine by PCR, but neither 5hmC nor 5mC changes in response to bisulfite 
treatment, and both and are read as cytosine. The quantity of 5hmC, however, is 
much smaller than that of 5mC. In this study, the average  value of 
hydroxymethylated genes with only a 5hmC peak and no 5mC peak was only 0.07, 
whereas that of methylated genes with only a 5mC peak and no 5hmC peak was 
0.54. The results for representative genes are shown in Fig. 25. Because the  value 
for 5hmC was sufficiently small, an Infinium assay was performed for 5mC 
detection.   
Fig. 25: Representative genes with an hmC peak, but no 
mC peak, e.g., ADAM17, and those with mC peak and no hmC 
peak, e.g., PAX7. The  values of the former genes were 
very low, e.g., 0.05 for ADAM17. The  values of the 
latter genes were markedly higher, e.g., 0.65 for PAX7. 
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7-8. Pyrosequencing analysis 
Validation for methylated locus was carried out by pyrosequencing as 
described previously [42]. Primers for pyrosequencing were designed by 
Pyrosequencing Assay Design Software ver.2.0 (QIAGEN) to amplify 
bisulfite-treated DNA region containing several CpG sites. Primer sequences are 
listed in Table 5. 
 
Table 5: Primers for pyrosequencing 
  
Gene strand Primer types Primer Sequence 
Anneal 
(°C) 
Product 
(bp) 
FRG1B bottom Forward GAGTGTTGTGGGAATGTGG 
56 101 
  
Reverse* TCCTCAAATACCCCCTCCAAAATTAAACT 
  
Sequenceing GGTGGAGAGTTATGGT 
HTRA1 bottom Forward* GGAGAGTGTAGGAGGGTTT 
58 134 
  
Reverse CCATCCCACCAACCCCCATC 
    Sequenceing CACCCCTACCAAACCAATAAACT 
* Primers with 5 -biotin tag. 
  
 
7-9. Analysis of miRNA 
For the microRNA (miRNA) expression analysis, Direct-zol RNA MiniPrep 
(Zymo Research) was used to extract total RNA, including miRNAs. The miRNA 
Microarray System with miRNA Complete Labeling and Hyb Kit Version 2.4 
(Agilent Technologies, Santa Clara, CA, USA) was used with 100 ng of total RNA as 
an input, following the manufacturer’s instructions. After washing, scanning was 
conducted using a DNA Microarray Scanner (Agilent Technologies) and the 
resulting image data were converted to numerical form using Feature Extraction 
ver. 10.7.1.1 (Agilent Technologies). The numerical data were normalized using 
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GeneSpring GX 12.0 (Agilent Technologies). For validation, candidate miRNA in 
mature form was obtained (Bioneer, Daejeon, Republic of Korea) and transfected 
into MKN7 and GES1 with a final concentration of 20 nM using Lipofectamine 2000 
(Invitrogen). 
 
7-10. Statistical analyses 
Statistical analyses of gene expression and methylation levels based on  
values were performed using Wilcoxon signed-rank test. Gene counts were 
compared using the 2 test. R program (www.r-project. org/) was implemented in 
those testing. P<0.05 was considered to be statistically significant. 
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Supplementary Table S1: EBV miRNA and the targeting human genes 
EBV miRNA Sequence Targeting human genes 
MIMAT0003720 ebv-miR-BART20-3p CAUGAAGGCACAGCCUGUUACC NM_024693 ECHDC3 
MIMAT0003719 ebv-miR-BART20-5p GUAGCAGGCAUGUCUUCAUUCC NM_203474 PORCN 
      NM_016592 GNAS 
      NM_000850 GSTM4 
      NM_058217 RAD51C 
      NM_018059 FLJ10324 
      NM_020956 PRX 
      NM_147149 GSTM4 
      XM_371176 LOC388550 
      XM_371009 LOC388327 
      NM_203318 MYO18A 
      NM_078471 MYO18A 
      NM_173557 RNF152 
      NM_000561 GSTM1 
      NM_203475 PORCN 
      NM_203476 PORCN 
      NM_022825 PORCN 
      NM_203473 PORCN 
      NM_001013617 LOC541469 
      NM_014521 SH3BP4 
      XM_498465 LOC439924 
      NM_000848 GSTM2 
      NM_019011 TRIAD3 
      NM_207111 TRIAD3 
      NM_207116 TRIAD3 
      NM_146421 GSTM1 
      NM_002442 MSI1 
      NM_014476 PDLIM3 
      NM_004959 NR5A1 
      XM_499595 LOC442764 
MIMAT0003716 ebv-miR-BART17-3p UUGUAUGCCUGGUGUCCCCUUA NM_018425 PI4KII 
MIMAT0003715 ebv-miR-BART17-5p AAGAGGACGCAGGCAUACAAGG NM_014964 EPN2 
      NM_148921 EPN2 
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      NM_017921 NPL4 
MIMAT0003714 ebv-miR-BART16 AUAGAGUGGGUGUGUGCUCUUG NM_001858 COL19A1 
MIMAT0003713 ebv-miR-BART15 AGUGGUUUUGUUUCCUUGAUAG NM_173455 PDE8A 
      NM_198830 ACLY 
      NM_001024211 S100A13 
      XM_499148 LOC441443 
      NM_000411 HLCS 
      XM_499149 LOC441444 
      NM_016577 RAB6B 
      NM_198321 GALNT10 
      NM_002605 PDE8A 
      NM_018308 ACOXL 
      NM_000860 HPGD 
      NM_006610 MASP2 
      XM_045421 C20orf194 
      NM_005935 AFF1 
      NM_020917 KIAA1559 
      NM_017540 GALNT10 
      NM_006650 CPLX2 
      NM_001008220 CPLX2 
      NM_005979 S100A13 
      NM_004089 TSC22D3 
      NM_001012960 C1orf84 
      NM_013254 TBK1 
      NM_001024210 S100A13 
      NM_005736 ACTR1A 
      NM_139021 MAPK15 
      NM_052919 KIAA1920 
      NM_173456 PDE8A 
      NM_005639 SYT1 
      NM_173457 PDE8A 
      NM_031886 KCNA7 
      NM_000136 FANCC 
      NM_002193 INHBB 
      NM_001005388 NFASC 
      NM_015090 NFASC 
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      NM_001096 ACLY 
      NM_001024213 S100A13 
      NM_001015881 TSC22D3 
      NM_001024212 S100A13 
      NM_003799 RNMT 
      NM_198057 TSC22D3 
      NM_014775 SFI1 
      NM_001007467 SFI1 
      NM_138294 PATE 
      NM_080473 GATA5 
      NM_173454 PDE8A 
      NM_001012993 C9orf152 
      NM_001029955 LOC285429 
      NM_002507 NGFR 
MIMAT0003423 ebv-miR-BART12 UCCUGUGGUGUUUGGUGUGGUUU NM_178225 FBXW5 
      NM_178226 FBXW5 
      NM_016734 PAX5 
      NM_144599 NIPA1 
      NM_031444 C22orf13 
      NM_003423 ZNF43 
      NM_030792 GDPD5 
      NM_052909 KIAA1909 
MIMAT0003422 ebv-miR-BART11-3p ACGCACACCAGGCUGACUGCC     
MIMAT0003421 ebv-miR-BART11-5p GACAGUUUGGUGCGCUAGUUGU XM_370758 LOC387978 
MIMAT0003415 ebv-miR-BART6-3p CGGGGAUCGGACUAGCCUUAGA     
MIMAT0003414 ebv-miR-BART6-5p GGUUGGUCCAAUCCAUAGGCUU NM_018717 MAML3 
      NM_021116 ADCY1 
      NM_017617 NOTCH1 
      NM_001025778 VRK3 
      NM_016440 VRK3 
      NM_001037553 AGPAT3 
      NM_020132 AGPAT3 
      NM_032831 C7orf19 
      NM_012407 PRKCABP 
      NM_001017995 KIAA1295 
      NM_019061 MTMR12 
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MIMAT0003390 ebv-miR-BART1-3p UAGCACCGCUAUCCACUAUGUCU NM_001002836 LOC126208 
MIMAT0000998 ebv-miR-BHRF1-3 UAACGGGAAGUGUGUAAGCACAC     
MIMAT0000995 ebv-miR-BHRF1-1 UAACCUGAUCAGCCCCGGAGUU     
MIMAT0003718 ebv-miR-BART19 UGUUUUGUUUGCUUGGGAAUGC NM_022733 SMAP1L 
      NM_006628 ARPP-19 
      NM_001001930 PPARA 
      NM_004014 DMD 
      NM_004012 DMD 
      NM_004007 DMD 
      NM_032871 TNFRSF19L 
      NM_014788 TRIM14 
      NM_004010 DMD 
      NM_006730 DNASE1L1 
      NM_001009932 DNASE1L1 
      NM_001009933 DNASE1L1 
      NM_001037172 ACPL2 
      NM_004011 DMD 
      NM_004235 KLF4 
      NM_004018 DMD 
      NM_152282 ACPL2 
      NM_024607 PPP1R3B 
      NM_001009934 DNASE1L1 
      NM_005036 PPARA 
      NM_001001929 PPARA 
      NM_020686 ABAT 
      NM_000663 ABAT 
      XM_379044 LOC284898 
      NM_002885 RAP1GA1 
      NM_001031717 CRELD1 
      NM_001007560 C14orf70 
      NM_001001928 PPARA 
      NM_005114 HS3ST1 
      NM_173551 SAMD6 
      NM_004020 DMD 
      NM_005587 MEF2A 
      NM_004021 DMD 
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      NM_002396 ME2 
      NM_006943 SOX12 
      NM_000109 DMD 
      NM_004009 DMD 
      NM_033221 TRIM14 
      NM_004006 DMD 
      NM_004015 DMD 
      NM_004023 DMD 
      NM_015513 CRELD1 
      NM_004013 DMD 
      NM_152222 TNFRSF19L 
      NM_004017 DMD 
      NM_004022 DMD 
      NM_004016 DMD 
MIMAT0003717 ebv-miR-BART18 CAAGUUCGCACUUCCUAUACAG NM_024989 PGAP1 
MIMAT0003426 ebv-miR-BART14-3p UAAAUGCUGCAGUAGUAGGGAU NM_139279 MCFD2 
      NM_199141 CARM1 
MIMAT0003425 ebv-miR-BART14-5p UACCCUACGCUGCCGAUUUACA NM_002028 FNTB 
      XM_376062 LOC400961 
MIMAT0003424 ebv-miR-BART13 UGUAACUUGCCAGGGACGGCUGA     
MIMAT0003420 ebv-miR-BART10 ACAUAACCAUGGAGUUGGCUGU NM_133625 SYN2 
MIMAT0003419 ebv-miR-BART9 UAACACUUCAUGGGUCCCGUAG     
MIMAT0003418 ebv-miR-BART8-3p GUCACAAUCUAUGGGGUCGUAG NM_018655 LENEP 
MIMAT0003417 ebv-miR-BART8-5p UACGGUUUCCUAGAUUGUACAG NM_001514 GTF2B 
      NM_001001665 FLJ16008 
MIMAT0003416 ebv-miR-BART7 CAUCAUAGUCCAGUGUCCAGGG NM_000664 ACACA 
      NM_198835 ACACA 
      NM_013246 CLCF1 
      NM_006033 LIPG 
      NM_002111 HD 
      NM_014732 KIAA0513 
      NM_145015 MRGPRF 
MIMAT0003413 ebv-miR-BART5 CAAGGUGAAUAUAGCUGCCCAUCG     
MIMAT0003412 ebv-miR-BART4 GACCUGAUGCUGCUGGUGUGCU NM_014571 HEYL 
      NM_001037553 AGPAT3 
      NM_020132 AGPAT3 
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      NM_052847 GNG7 
MIMAT0003411 ebv-miR-BART3-3p CGCACCACUAGUCACCAGGUGU     
MIMAT0003410 ebv-miR-BART3-5p AACCUAGUGUUAGUGUUGUGCU NM_021943 ZFAND3 
      NM_016605 FAM53C 
MIMAT0001000 ebv-miR-BART2 UAUUUUCUGCAUUCGCCCUUGC NM_024671 FLJ23436 
      NM_021973 HAND2 
      NM_032385 C5orf4 
      NM_020452 ATP8B2 
      NM_016348 C5orf4 
      NM_017586 C9orf7 
      NM_000809 GABRA4 
MIMAT0000999 ebv-miR-BART1-5p UCUUAGUGGAAGUGACGUGCUGU     
MIMAT0000997 ebv-miR-BHRF1-2-3p UAUCUUUUGCGGCAGAAAUUGAA     
MIMAT0000996 ebv-miR-BHRF1-2-5p AAAUUCUGUUGCAGCAGAUAGC NM_021998 ZNF6 
      NM_006137 CD7 
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